Unione Europea - islandese - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mergæxli - Æxlishemjandi lyf - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

navamedic asa - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

vital pharma nordic aps - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 1 g

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 500 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 800 mg

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 100 mg/ml

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 50 mg/ml

Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - sotalolum hýdróklóríð - tafla - 40 mg